Capital Group International Inc. CA decreased its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Get Rating) by 44.0% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 60,056 shares of the pharmaceutical company’s stock after selling 47,117 shares during the quarter. Capital Group International Inc. CA’s holdings in Vertex Pharmaceuticals were worth $15,673,000 at the end of the most recent quarter.
Other institutional investors have also recently modified their holdings of the company. Sittner & Nelson LLC raised its position in shares of Vertex Pharmaceuticals by 66.7% during the 1st quarter. Sittner & Nelson LLC now owns 125 shares of the pharmaceutical company’s stock worth $33,000 after purchasing an additional 50 shares during the last quarter. Steward Financial Group LLC acquired a new position in Vertex Pharmaceuticals in the 1st quarter valued at $34,000. GPS Wealth Strategies Group LLC raised its holdings in Vertex Pharmaceuticals by 104.1% in the 1st quarter. GPS Wealth Strategies Group LLC now owns 149 shares of the pharmaceutical company’s stock valued at $39,000 after acquiring an additional 76 shares during the last quarter. Cordasco Financial Network acquired a new position in Vertex Pharmaceuticals in the 1st quarter valued at $40,000. Finally, Vestor Capital LLC acquired a new position in Vertex Pharmaceuticals in the 1st quarter valued at $41,000. 91.33% of the stock is currently owned by institutional investors and hedge funds.
Analysts Set New Price Targets
Several research analysts have weighed in on VRTX shares. Morgan Stanley boosted their price target on Vertex Pharmaceuticals from $250.00 to $253.00 and gave the company an “equal weight” rating in a report on Monday, August 8th. SVB Leerink began coverage on shares of Vertex Pharmaceuticals in a research note on Monday, May 23rd. They set a “market perform” rating and a $265.00 price objective for the company. Cowen boosted their price objective on shares of Vertex Pharmaceuticals from $305.00 to $310.00 in a research note on Monday, June 13th. Argus boosted their price objective on shares of Vertex Pharmaceuticals from $275.00 to $280.00 and gave the company a “buy” rating in a research note on Monday, June 13th. Finally, Piper Sandler boosted their price objective on shares of Vertex Pharmaceuticals from $256.00 to $288.00 and gave the company a “neutral” rating in a research note on Tuesday, August 16th. Six equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Vertex Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $291.65.
Vertex Pharmaceuticals Stock Performance
NASDAQ:VRTX opened at $284.86 on Thursday. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.50 and a quick ratio of 4.36. The firm has a 50-day moving average of $287.96 and a two-hundred day moving average of $271.43. The stock has a market cap of $73.05 billion, a P/E ratio of 23.03, a PEG ratio of 2.08 and a beta of 0.45. Vertex Pharmaceuticals Incorporated has a 1-year low of $176.36 and a 1-year high of $305.95.
Vertex Pharmaceuticals (NASDAQ:VRTX – Get Rating) last posted its quarterly earnings data on Thursday, August 4th. The pharmaceutical company reported $3.60 earnings per share for the quarter, beating analysts’ consensus estimates of $3.12 by $0.48. The company had revenue of $2.20 billion during the quarter, compared to analysts’ expectations of $2.13 billion. Vertex Pharmaceuticals had a net margin of 38.26% and a return on equity of 31.22%. The firm’s revenue for the quarter was up 22.5% on a year-over-year basis. During the same period in the prior year, the company posted $2.80 EPS. On average, research analysts expect that Vertex Pharmaceuticals Incorporated will post 12.56 earnings per share for the current fiscal year.
Vertex Pharmaceuticals Company Profile
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation.
- Get a free copy of the StockNews.com research report on Vertex Pharmaceuticals (VRTX)
- Is This Medical Gear Maker Ready To Continue Its Rally?
- The Five (5) Hottest Stocks To Watch Ahead Of Q3 Earnings
- Has Take-Two Interactive Devolved into a One-Trick Pony?
- Four Cheap Stocks With Interesting Insider Activity
- Can Health Drink Maker Celsius Outrun Its Monster Rival?
Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.